These findings bring new insights into loss of post-transcriptional regulatory circuits during CRC tumor development and demonstrate that HDAC inhibitors could restore TTP expression in cancer cells, thus providing clinical perspectives for these compounds. This evidence concerns the gene HDAC9 and cancer.